Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, announced participation by Dr. Neal Walker, its President and CEO, in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference. The event will be available starting January 10, 2022, at 7:00 a.m. ET, and interested parties can access the webcast through the "Events" page on Aclaris' website. The company is focused on developing innovative drug candidates for immuno-inflammatory diseases, addressing significant unmet medical needs.

WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, which will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.

A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com

FAQ

When will Aclaris Therapeutics participate in the H.C. Wainwright BioConnect Virtual Conference?

Aclaris Therapeutics will participate in the conference starting January 10, 2022, at 7:00 a.m. ET.

How can I access the Aclaris Therapeutics webcast?

The webcast can be accessed through the "Events" page of the Investors section on Aclaris' website.

What is the focus of Aclaris Therapeutics' drug development?

Aclaris Therapeutics focuses on developing novel drug candidates for immuno-inflammatory diseases.

Who is the CEO of Aclaris Therapeutics?

Dr. Neal Walker is the President and CEO of Aclaris Therapeutics.

How long will the Aclaris webcast be available for viewing?

The webcast will be archived for at least 30 days on Aclaris' website.